1st Patient Dosed in Phase 1/2 Trial Testing CAR T-cell Therapy MB-102 in AML
News
The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating the safety and efficacy of MB-102 — a CD123-targeted CAR T-cell therapy — in adults with ... Read more